Belantamab mafodotin (interim monograph) DRUG NAME: Belantamab mafodotin SYNONYM(S): GSK28579161 COMMON TRADE NAME(S): CLASSIFICATION: miscellaneous. Special pediatric considerations are noted when applicable, otherwise adult provisions apply.
Belantamab mafodotin was approved earlier this year in the United States and in the European Union for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.
The drug is currently under investigation in multiple studies. If approved by the FDA, belantamab mafodotin would be the first anti-BCMA treatment available to patients. References: 1. Mafodotin, a potent microtubule disruptor, prevents multiple myeloma cells from dividing, leading to apoptosis. 1,4 Enhances immune-mediated actions: BLENREP has an afucosylated antibody that enhances recruitment and activation of immune effector cell-mediated antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP).
- Folktandvarden kvissleby
- Kalium infusion rate
- Rh betong eskilstuna
- Koreografer tari merak
- Ny legitimation pris
- Haninge nya bvc
The antibody has been designed to attach to a protein called B-cell maturation antigen (BCMA), which is present on the surface of abnormal immature plasma cells (myeloma cells). Belantamab mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with a multimodal mechanism of action. In the first-in-human, phase 1 DREAMM-1 study, belantamab mafodotin showed promising anti-myeloma activity, inducing responses in heavily pre-treated patients with relapsed or refractory multiple myeloma. Added value of this study Belantamab mafodotin was approved earlier this year in the United States and in the European Union for the treatment of patients with relapsed and/or refractory multiple myeloma who have received at least four prior therapies including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. 2021-04-05 · Belantamab mafodotin, a B-cell maturation antigen drug-antibody conjugate, is a first-in-class humanised moAb containing a distinct microtubule-disrupting agent: monomethyl auristatin-F. Its distinctive anti-MM activity includes antibody-dependent cellular cytotoxicity and phagocytosis, as well as direct cytotoxicity caused by internalisation of monomethyl auristatin-F. Belantamab mafodotin är inte godkänd på någon annan marknad [3].
Sep 9, 2020 To define and describe the accepted indications for Blenrep (belantamab mafodotin-blmf) usage in the treatment of cancer, including FDA
Behov av sammanhållen hantering av läkemedel vid denna indikation. 2020-06-24. belantamab mafodotin. Jemperli vid behandling av endometriecancer.
Dec 17, 2020 GSK poised to leap back into the oncology market with more positive belantamab mafodotin results — but BCMA rivals are swarming in behind
Belantamab mafodotin (interim monograph) DRUG NAME: Belantamab mafodotin SYNONYM(S): GSK28579161 COMMON TRADE NAME(S): CLASSIFICATION: miscellaneous. Special pediatric considerations are noted when applicable, otherwise adult provisions apply. International non-proprietary name: belantamab mafodotin Procedure No. EMEA/H/C/004935/0000 Note Assessment report as a dopted by the CHMP with all information of a commercially confidential nature deleted.
Background: Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study. Belantamab mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with a multimodal mechanism of action. In the first-in-human, phase 1 DREAMM-1 study, belantamab mafodotin showed promising anti-myeloma activity, inducing responses in heavily pre-treated patients with relapsed or refractory multiple myeloma. Added value of this study
The active substance in Blenrep, belantamab mafodotin, consists of a monoclonal antibody (a type of protein) attached to a cytotoxic (cell-killing) molecule. The antibody has been designed to attach to a protein called B-cell maturation antigen (BCMA), which is present on the surface of abnormal immature plasma cells (myeloma cells).
Stadshusbron
BLENREP.
Belantamab mafodotin-blmf was evaluated in DREAMM-2 (NCT 03525678), an open-label, multicenter trial.
Sport management flashback
allmänbildning quiz med svar
falska märkeskläder från kina
hans dahlqvist linköping
göran kling
Ja. Nytt 2021 isatuximab (Sarclisa). L01XC39 belantamab mafodotin. Sjukhusvård. Ja. Nytt 2021 belantamab mafodotin (Blenprep). L01XCÖÖ.
Background: Belantamab mafodotin (GSK2857916), an immunoconjugate targeting B-cell maturation antigen, showed single-agent activity in the phase 1 DREAMM-1 study in heavily pre-treated patients with relapsed or refractory multiple myeloma. We further investigated the safety and activity of belantamab mafodotin in the DREAMM-2 study. Belantamab mafodotin (GSK2857916) is a first-in-class, anti-BCMA immunoconjugate with a multimodal mechanism of action.